News regarding the bio-tech firm, Viatris Inc (VTRS), indicates several relevant developments. Firstly, Bernstein and Goldman Sachs have initiated coverage of the company. A series of shareholder alerts and potential lead plaintiff opportunities in securities fraud lawsuits further color the company's reputation. Q2 2025 earnings call details have been unveiled and reiteration of the company's 2025 outlook, despite reportedly lower-than-expected sales for Q1. Additionally, Zacks Industry outlook has spotlighted Viatris along with other bio-tech companies like Sandoz and Teva Pharmaceuticals.
There are several class action lawsuits outstanding against the company and related deadlines facing investors. Viatris has announced numerous positive results both in terms of quarterly earnings and in breakthrough clinical trials such as the new low-dose birth control patch, Xulane, and Fast-Acting Meloxicam for moderate-to-severe acute pain.
Notwithstanding these positives, analyst sentiment has generally been cautious, with repeated neutral ratings from Goldman Sachs. The company has participated in investor conferences and conducted major leadership reshuffles, with ex-heads of Pfizer and AbbVie joining the board. As per the company's financial reports, Q4 2023 and Q4 2024 were positive and there are agreements on remaining planned divestitures.Scott A. Smith has been announced the new CEO, effective April 2023, and the firm has showcased recent sustainability efforts.
Viatris VTRS News Analytics from Mon, 27 Feb 2023 08:00:00 GMT to Thu, 12 Jun 2025 20:30:00 GMT - Rating -3 - Innovation 3 - Information 6 - Rumor -1
